Phase 4
N=10
Sphenopalatine Ganglion Blocks RCT
Migraine
Bottom Line
View on ClinicalTrials.gov: NCT03666663 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcome: Primary: Number of Participants With a Reduction in Headache Days From Baseline to Month 8 of Treatment — 3; 1; 1; 0 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Lidocaine (Drug); Bupivacaine (Drug); Ropivacaine (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, San Francisco
- Primary completion
- Jul 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With a Reduction in Headache Days From Baseline to Month 8 of Treatment |
3; 1; 1; 0 | — |
Summary
RCT of Sphenopalatine Ganglion (SPG) Blocks using anesthetics vs. placebo for migraine.
Eligibility Criteria
Inclusion Criteria
- Age 18 years or more at time of consent
- Current patients in the UCSF Headache Center eligible to receive SPG blocks for migraine and would otherwise receive treatment clinically
- Ability to provide consent for the research study
Exclusion Criteria
- Pregnant or breast feeding within 4 weeks of enrollment
- Inability to communicate with the study team
- Patients who cannot read and understand English
- Deemed unsuitable for enrollment in study by the investigator
- Allergy to local anesthetics or saline
Data sourced from ClinicalTrials.gov (NCT03666663). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.